Immatics N.V.
IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecificsā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.81
Price+0.35%
$0.02
1Y
Price
Market Cap
$706.206m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$144.148m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$21.584m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.15
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$536.606m
$641.692m
Assets$105.086m
Liabilities$18.387m
DebtDebt to Assets
2.9%
-4.1x
Debt to EBITDAFree Cash Flow
-$170.070m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company